NL300164I1 - Gaba- en L-glutaminezuuranaloga voor behandeling tegen convulsies. - Google Patents
Gaba- en L-glutaminezuuranaloga voor behandeling tegen convulsies.Info
- Publication number
- NL300164I1 NL300164I1 NL300164C NL300164C NL300164I1 NL 300164 I1 NL300164 I1 NL 300164I1 NL 300164 C NL300164 C NL 300164C NL 300164 C NL300164 C NL 300164C NL 300164 I1 NL300164 I1 NL 300164I1
- Authority
- NL
- Netherlands
- Prior art keywords
- gaba
- glutamic acid
- acid analogues
- treatment against
- compound
- Prior art date
Links
- 206010010904 Convulsion Diseases 0.000 title 1
- 125000003338 L-glutaminyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 title 1
- 230000036461 convulsion Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88608092A | 1992-05-20 | 1992-05-20 | |
PCT/US1993/004680 WO1993023383A1 (en) | 1992-05-20 | 1993-05-18 | Gaba and l-glutamic acid analogs for antiseizure treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NL300164I1 true NL300164I1 (nl) | 2005-01-03 |
NL300164I2 NL300164I2 (nl) | 2005-02-01 |
Family
ID=25388336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL300164C NL300164I2 (nl) | 1992-05-20 | 2004-11-22 | Gaba- en L-glutaminezuuranaloga voor behandeling tegen convulsies. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0641330B1 (nl) |
JP (2) | JP3856816B2 (nl) |
KR (1) | KR950701625A (nl) |
AT (1) | ATE207052T1 (nl) |
AU (1) | AU677008B2 (nl) |
CA (1) | CA2134674C (nl) |
CZ (1) | CZ286106B6 (nl) |
DE (2) | DE69330949T2 (nl) |
DK (1) | DK0641330T3 (nl) |
ES (1) | ES2165857T3 (nl) |
FI (1) | FI945426A (nl) |
HK (1) | HK1011022A1 (nl) |
HU (2) | HU222339B1 (nl) |
LU (1) | LU91112I2 (nl) |
NL (1) | NL300164I2 (nl) |
NO (1) | NO944370L (nl) |
NZ (1) | NZ253459A (nl) |
PT (1) | PT641330E (nl) |
RU (2) | RU2140901C1 (nl) |
SG (1) | SG48288A1 (nl) |
SK (1) | SK283281B6 (nl) |
WO (1) | WO1993023383A1 (nl) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113052A0 (en) * | 1994-03-23 | 1995-06-29 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their use in gene therapy |
HU223841B1 (hu) * | 1994-07-27 | 2005-02-28 | Warner-Lambert Company | Gabepentin alkalmazása szorongás és pánik kezelésére alkalmazható gyógyszerkészítmények előállítására |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5616793A (en) * | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
US5637767A (en) * | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
WO1998003167A1 (en) | 1996-07-24 | 1998-01-29 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
EP0937032B1 (en) * | 1996-10-23 | 2007-05-09 | Warner-Lambert Company LLC | Substituted gamma aminobutyric acids as pharmaceutical agents |
AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
IL134165A0 (en) | 1997-09-08 | 2001-04-30 | Warner Lambert Co | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
KR100602047B1 (ko) * | 1998-05-15 | 2006-07-19 | 워너-램버트 캄파니 엘엘씨 | 감마-아미노부티르산 유도체의 안정화된 제약 제제 및그의 제조 방법 |
US6359005B1 (en) * | 1998-10-16 | 2002-03-19 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
DE60040784D1 (de) * | 1999-04-08 | 2008-12-24 | Warner Lambert Co | Verfahren zur behandlung von inkontinenz |
US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
BR0011727A (pt) * | 1999-06-10 | 2002-03-05 | Warner Lambert Co | ácidos 3-propil gama-aminobutìricos mono- e dissubstituìdos |
US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
WO2002022622A2 (en) | 2000-09-13 | 2002-03-21 | Georgetown University | Synthesis of 2-hydroxymethylglutamic acid and congeners thereof |
EP1343805A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US6462084B1 (en) * | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
AU2002345638A1 (en) | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
IL159299A0 (en) | 2001-06-11 | 2004-06-01 | Xenoport Inc | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
WO2003080588A1 (en) | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
US20030225149A1 (en) * | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
AU2003297927A1 (en) | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
CA2505788A1 (en) | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
KR20050085563A (ko) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
WO2005025562A1 (en) | 2003-09-11 | 2005-03-24 | Xenoport, Inc. | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
ATE449633T1 (de) | 2003-09-12 | 2009-12-15 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
RU2377234C2 (ru) * | 2003-09-17 | 2009-12-27 | Ксенопорт, Инк. | Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк |
NZ579515A (en) | 2003-09-17 | 2011-09-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
SI1677767T1 (sl) | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
WO2005060968A1 (en) | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
AU2005301970B2 (en) | 2004-11-04 | 2011-06-02 | Arbor Pharmaceuticals, Llc | Gabapentin prodrug sustained release oral dosage forms |
EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
EA017171B1 (ru) | 2006-12-22 | 2012-10-30 | Рекордати Айерленд Лимитед | КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП) |
AU2008339583A1 (en) * | 2007-12-26 | 2009-07-02 | Generics [Uk] Limited | Processes to pregabalin |
EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
TWI369202B (en) | 2008-01-25 | 2012-08-01 | Xenoport Inc | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
EP2110372A1 (en) | 2008-04-16 | 2009-10-21 | Chemo Ibérica, S.A. | Intermediates for the preparation of Pregabalin and process for their preparation |
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
ES2362913B1 (es) | 2009-12-24 | 2012-05-24 | Moehs Iberica S.L. | Nuevo método para la preparación de (s)-pregabalina. |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
JP5807006B2 (ja) | 2010-03-18 | 2015-11-10 | 第一三共株式会社 | シクロアルキル基で置換されたイミダゾール誘導体 |
KR20130006620A (ko) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
EP2383255A1 (en) | 2010-04-28 | 2011-11-02 | Lacer, S.A. | New compounds, synthesis and use thereof in the treatment of pain |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
US8946267B2 (en) | 2010-07-30 | 2015-02-03 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2415460A1 (de) | 2010-08-03 | 2012-02-08 | ratiopharm GmbH | Orale Darreichungsform von Pregabalin |
US8212072B2 (en) | 2010-08-13 | 2012-07-03 | Divi's Laboratories, Ltd. | Process for the preparation of pregabalin |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
EP2527319A1 (en) | 2011-05-24 | 2012-11-28 | Laboratorios Del. Dr. Esteve, S.A. | Crystalline forms of pregabalin and co-formers in the treatment of pain |
WO2013100873A1 (en) | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
ES2423254B1 (es) | 2012-02-15 | 2014-03-26 | Laboratec, S.L. | Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
US10130715B2 (en) | 2013-01-28 | 2018-11-20 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor |
JP2016540771A (ja) | 2013-12-17 | 2016-12-28 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | セロトニン−ノルアドレナリン再取り込み阻害薬(snri)およびシグマ受容体リガンドの組み合わせ |
SG11201604478UA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | Gabapentinoids and sigma receptor ligands combinations |
WO2016075082A1 (en) | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
CA3099775A1 (en) | 2018-05-14 | 2019-11-21 | Xgene Pharmaceutical Inc. | Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin |
DE202018105573U1 (de) | 2018-09-27 | 2018-10-19 | Laboratec | Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4840460B1 (nl) * | 1969-02-05 | 1973-11-30 | ||
US4173541A (en) * | 1978-06-05 | 1979-11-06 | Cincinnati Milacron Chemicals Inc. | Polynuclear hindered phenols and stabilized organic materials containing the phenols |
US4322440A (en) * | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
US4479005A (en) * | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
US4771038A (en) * | 1986-01-21 | 1988-09-13 | Ici Americas Inc. | Hydroxamic acids |
US4814342A (en) * | 1986-10-31 | 1989-03-21 | Pfizer Inc. | Nor-statine and nor-cyclostatine polypeptides |
KR930003864B1 (ko) * | 1990-10-19 | 1993-05-14 | 한국과학기술연구원 | d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법 |
AU9137091A (en) * | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
US5198548A (en) * | 1992-01-30 | 1993-03-30 | Warner-Lambert Company | Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof |
-
1993
- 1993-05-18 HU HU9403310A patent/HU222339B1/hu active Protection Beyond IP Right Term
- 1993-05-18 DE DE69330949T patent/DE69330949T2/de not_active Expired - Lifetime
- 1993-05-18 RU RU96124481A patent/RU2140901C1/ru active
- 1993-05-18 CZ CZ19942849A patent/CZ286106B6/cs not_active IP Right Cessation
- 1993-05-18 SK SK1395-94A patent/SK283281B6/sk not_active IP Right Cessation
- 1993-05-18 ES ES93925173T patent/ES2165857T3/es not_active Expired - Lifetime
- 1993-05-18 AT AT93925173T patent/ATE207052T1/de active
- 1993-05-18 JP JP50380794A patent/JP3856816B2/ja not_active Expired - Lifetime
- 1993-05-18 NZ NZ253459A patent/NZ253459A/en not_active IP Right Cessation
- 1993-05-18 CA CA002134674A patent/CA2134674C/en not_active Expired - Lifetime
- 1993-05-18 KR KR1019940704158A patent/KR950701625A/ko not_active Application Discontinuation
- 1993-05-18 HU HU9702482A patent/HU222776B1/hu active IP Right Grant
- 1993-05-18 EP EP93925173A patent/EP0641330B1/en not_active Expired - Lifetime
- 1993-05-18 PT PT93925173T patent/PT641330E/pt unknown
- 1993-05-18 RU RU94046105/04A patent/RU94046105A/ru unknown
- 1993-05-18 WO PCT/US1993/004680 patent/WO1993023383A1/en active IP Right Grant
- 1993-05-18 SG SG1996008718A patent/SG48288A1/en unknown
- 1993-05-18 DK DK93925173T patent/DK0641330T3/da active
- 1993-05-18 AU AU43794/93A patent/AU677008B2/en not_active Ceased
- 1993-05-18 DE DE1993630949 patent/DE122004000039I2/de active Active
-
1994
- 1994-11-16 NO NO944370A patent/NO944370L/no unknown
- 1994-11-18 FI FI945426A patent/FI945426A/fi not_active Application Discontinuation
-
1998
- 1998-11-17 HK HK98112078A patent/HK1011022A1/xx not_active IP Right Cessation
-
2004
- 2004-03-16 JP JP2004075406A patent/JP4297814B2/ja not_active Expired - Lifetime
- 2004-10-06 LU LU91112C patent/LU91112I2/fr unknown
- 2004-11-22 NL NL300164C patent/NL300164I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300164I1 (nl) | Gaba- en L-glutaminezuuranaloga voor behandeling tegen convulsies. | |
MX9102241A (es) | Analogos de gaba y de acido l-glutamico para tratamiento contra ataques. | |
ATE215078T1 (de) | Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern | |
EP0989113A4 (en) | METHOD FOR PRODUCING 2-AMINOMALONIC ACID DERIVATIVES AND 2-AMINO-1,3-PROPANEDIOL DERIVATIVES AND INTERMEDIATE PRODUCTS FOR PRODUCING THESE COMPOUNDS | |
IT1196334B (it) | Processo per la risoluzione ottica di miscugli racemi di acidi alfanaftil-propionici | |
PT91145A (pt) | Processo para a sintese de amino-acidos opticamente activos | |
MX9302970A (es) | Analogos de acido l-glutamico y gaba para tratamiento anti-ataque. | |
DE69327092D1 (de) | Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung | |
GEP19970937B (en) | Method of producing derivatives of muramyldipeptide |